[Skip to Content]
[Skip to Content Landing]
Views 3,657
Citations 0
Clinical Trials Update
July 24/31, 2018

Brain Marker Predicts Depression Outcomes

JAMA. 2018;320(4):332. doi:10.1001/jama.2018.10156

Individuals with major depression and higher rostral anterior cingulate cortex (rACC) theta activity prior to treatment had better outcomes than those with less rACC theta activity at baseline, according to a study in JAMA Psychiatry.

The 296 patients with major depressive disorder were randomized to receive sertraline hydrochloride or placebo for 8 weeks. Among 248 patients with usable electroencephalographic (EEG) recordings, higher rACC theta activity at baseline and week 1 predicted greater depressive-symptom improvement in both placebo and treatment groups, even after controlling for other clinical and demographic variables associated with treatment outcome.

First Page Preview View Large
First page PDF preview
First page PDF preview